Aclaris Therapeutics (ACRS) vs Evotec (EVO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aclaris Therapeutics (ACRS) has outperformed Evotec (EVO) over the past year, gaining 99.5% versus a loss of 60.6%. Over five years, ACRS leads with a -77.5% price change compared with -93.1% for EVO. Evotec is the larger company by market cap ($558.0 million vs $557.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRS | EVO |
|---|---|---|
| Share price | $3.79 | $1.57 |
| Market cap | $557.88M | $557.96M |
| 1-day change | +11.47% | -2.48% |
| YTD return | +25.91% | -49.03% |
| 1-year return | +99.47% | -60.55% |
| 5-year return | -77.45% | -93.05% |
| EPS (TTM) | $-0.58 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.60 | $4.27 |
| 52-week low | $1.74 | $1.50 |
| Distance from 52-week high | -42.58% | -63.23% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +168.60% | +164.97% |
| Average volume | 2.48M | 103.98K |
| Shares outstanding | 147.20M | 355.39M |
| Employees | 69 | 4,461 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRS has outperformed EVO by 160.0 percentage points over the past year.
About Aclaris Therapeutics
ACRS stock →Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Evotec
EVO stock →Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics.
Health Care · Biotechnology: Pharmaceutical Preparations · 4,461 employees
ACRS vs EVO FAQ
Which is bigger, Aclaris Therapeutics or Evotec?
Evotec (EVO) is larger, with a market capitalization of $557.96M compared with $557.88M for Aclaris Therapeutics (ACRS).
Which stock has performed better over the past year, ACRS or EVO?
ACRS returned +99.47% over the past 12 months, compared with -60.55% for EVO (price return, excluding dividends). Past performance does not predict future results.
Are Aclaris Therapeutics and Evotec in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.